侵袭性胸腺瘤,Invasive thymoma
1)Invasive thymoma侵袭性胸腺瘤
1.Expression and clinical significance of β-catenin and c-myc in invasive thymoma;β-catenin和c-myc在侵袭性胸腺瘤中的表达及临床意义
2.In 29 cases pSS with maligancies patients,there are lymphoma 8 cases(NHL 7 cases,one with unknow type),breast cancer 4 cases, Myeloma,Invasive thymoma,Lung cancer,gastric carcinoma,Liver cancer,colon carcinoma and squamous cell carcinoma of touge 2 cases respectively;uterine cervix cancer,renal cortical carcinoma,thyroid carcinoma and carcinoma of parotid gland 1 cases respectively.在29例pSS合并恶性肿瘤患者中淋巴瘤占8例(非霍奇金淋巴瘤7例,不明分型1例),乳腺癌4例,多发性骨髓瘤、侵袭性胸腺瘤、肺癌、胃腺癌、结肠癌、舌鳞癌各2例,肝癌、宫颈癌、肾癌、甲状腺癌、腮腺粘液表皮样癌各1例。
英文短句/例句
1.Pathological Features and Surgical Effect of Invasive Thymoma侵袭性胸腺瘤的病理特征及手术治疗效果观察
2.Clinical and Radiologic Studies on Invasive Pituitary Adenomas;侵袭性垂体腺瘤的影像学与实验研究
3.The Diagnosis Criteria of the Invasive Pituitary Adenoma by MRI and the Evalution;侵袭性垂体腺瘤MRI诊断标准及其评价
4.The study on expression XIAP,caspase-3 and smac in invasive pituitary adenomas侵袭性垂体腺瘤smac,XIAP,caspase-3的表达
5.Non-invasive malignant pleomorphic adenoma of the submandibular gland:Report of one lase下颌下腺非侵袭性恶性多形性腺瘤1例报告
6.Relationships between expressions of ER,PTTG,PCNA in human prolactinomas and tumor invasiveness泌乳素腺瘤ER、PTTG、PCNA的表达与肿瘤侵袭性的关系
7.Establishment of differential expression profiles from invasive and non-invasive pituitary adenomas侵袭性与非侵袭性垂体腺瘤的蛋白质差异表达谱的建立(英文)
8.Study on Correlation between Osteopontin and Pituitary Adenomas Invasiveness;骨桥蛋白与垂体腺瘤侵袭性的相关性研究
9.Expressions and Related Research of VEGF and bFGF in Invasive Pituitary Adenomas侵袭性垂体腺瘤中VEGF和bFGF的表达及相关性研究
10.Study on Correlation between Osteopontin、Matrix Metalloproteinase-9、Microvessel Density and Pituitary Adenomas InvasivenessOPN、MMP-9、和MVD与垂体腺瘤侵袭性的相关性研究
11.Effect of Combined Treatment on Invasive Pituitary Adenoma in 58 Patients and Relationship between the Expression of Ki-67 Antigen and Invasiveness in the Pituitary Adenoma;侵袭性垂体腺瘤综合治疗及Ki-67抗原表达与垂体腺瘤侵袭性的关系
12.Sebaceous gland carcinoma is a rare, aggressive, skin tumour.皮脂腺癌是一种罕见的侵袭性皮肤肿瘤。
13.The Studies of Relationship between Invasiveness Pituitary Adenoma and Expression, Regulation of uPA System;垂体腺瘤侵袭性与uPA系统表达、调控的实验研究
14.The Study on Expression and Relationship between MMP-9、TIMP-1、HPA、CD34 and Invasiveness of Pituitary Adenomas;MMP-9、TIMP-1、HPA及CD34与垂体腺瘤侵袭性关系的研究
15.The Study on Expression and Relationship between hPTTG、bFGF、P53 and Invasiveness of Pituitary Adenomas;hPTTG、bFGF及P53与垂体腺瘤侵袭性关系的研究
16.The Relationship between Invasiveness and Expression of CXCR4 and Angiogenesis in Human Pituitary Adenomas;CXCR4表达、血管生成与垂体腺瘤侵袭性关系的研究
17.The Relationship between the Presentation of FAK, VEGF MVD and the Invasiveness of Pituitary Adenoma;FAK、VEGF、MVD的表达与垂体腺瘤侵袭性的关系
18.The Study on Expression and Relationship between MMP-2、TIMP-2、CD147 and Invasiveness of Pituitary Adenomas;MMP-2、TIMP-2及CD147与垂体腺瘤侵袭性关系的研究
相关短句/例句
invasive pituitary adenoma侵袭性垂体腺瘤
1.Gamma knife radiosurgery forinvasive pituitary adenoma;侵袭性垂体腺瘤的伽玛刀治疗
2.Research and treatment ofinvasive pituitary adenomas: current status and future expectation;侵袭性垂体腺瘤研究现状及进展
3.The analysis of clinial diagnosis and treatment ofinvasive pituitary adenomas．;侵袭性垂体腺瘤的临床诊治分析
3)Invading pituitary ademona垂体侵袭性腺瘤
4)Non-invasive pituitary adenoma非侵袭性垂体腺瘤
1.Methods Expression of CD44s and CD44_(v5) were detected in samples of pituitary adenoma(20 invasive and 18 non-invasive pituitary adenoma), using S-P immunohistochemical staining method.18例非侵袭性垂体腺瘤中CD44s、CD44v5阳性率分别为27。
5)invasive prolactinomas侵袭性垂体泌乳素腺瘤
1.Methods Expressions of Gal-3 were evaluated by immunohistochemistry using polyclonal antibody in 16invasive prolactinomas and 16 prolactinomas.方法采用免疫组织化学方法,测定16例侵袭性垂体泌乳素腺瘤和16例非侵袭性垂体泌乳素腺瘤中Gal-3的表达水平。
6)pituitary adenomas invading cavernous sinus海绵窦侵袭性垂体腺瘤
延伸阅读
胸腺多肽,胸腺素F5,胸腺素,胸腺素注射液药物名称：胸腺肽注射液英文名：Thymopetidum Injection别名：胸腺多肽,胸腺素F5,胸腺素,胸腺素注射液、胸腺因子注射液、胸腺因子D注射液。性状：本品为无色或微黄色澄明液体。药理作用： 促使骨髓产生的干细胞转变为T细胞，从而增强细胞免疫功能。 从健康乳牛胸腺中提取制得的多肽类细胞免疫调节剂。可作用于T淋巴细胞分化的各个阶段，有调节和增强人体免疫功能的作用，可提高机体的防病抗病能力，缩短感染性疾病的治疗周期。用于原发或继发性免疫缺陷病或免疫功能失调引起的各种疾病、自身免疫性疾病以及病毒或细菌性感染和肿瘤的辅助治疗。适应症： 用于免疫缺陷病、恶性肿瘤及病毒性疾病。 用于治疗各种原发性或继发性T细胞缺陷病，某些自身免疫性疾病，各种细胞免疫功能低下的疾病及肿瘤的辅助治疗.用量用法： 肌注：每次2-10mg，每日或隔日1次。对于胸腺发育不全症患者应做替代治疗，每日1mg/kg，病情好转后改为维持量每周1mg/kg。 静脉滴注：一次20～80mg，溶于500ml，0.9%氯化钠注射液或5%葡萄糖注射液，一日1次或遵医嘱。注意事项：1.对于过敏体质者，注射前或治疗终止后再用药时需做皮内敏感试验（配成25μg/ml的溶液，皮内注射0.1ml），阳性反应者禁用。2.本品如出现混浊或絮状沉淀物等异常变化，禁忌使用。3. 有发热、头晕、皮疹等。规格： 注射剂：2mg/2ml；5mg/2ml。2ml:5mg;2ml：20mg类别：免疫调节剂
